#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Parkinson's disease Fibrodysplasia ossificans progressiva Hereditary neuropathic amyloidosis Kaposi's sarcoma Gaucher's disease type III Myelodysplastic syndrome with excess blasts Brain injury Rectal cancer Metachromatic leukodystrophy Hepatobiliary cancer Friedreich's ataxia Cutaneous T-cell lymphoma stage II Anti-myelin-associated glycoprotein associated polyneuropathy Carcinoid syndrome Trigeminal neuralgia More trials…

    Learn about Rare Diseases

    Choroid melanoma Glycogen storage disease type I – Basic Information Medulloblastoma – Diagnostics Retinitis pigmentosa – Diagnostics Netherton’s syndrome – Trials in Disease Basal cell naevus syndrome – Trials in Disease Myelodysplastic syndrome Mantle cell lymphoma Ornithine transcarbamoylase deficiency – Life with Disease Pemphigoid – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pitolisant Nilotinib Ceftolozane Fasudil Hydrochloride Ima203Cd8 Tamsulosin Hydrochloride L-Ascorbic Acid Remestemcel Birtamimab Ly3537982 Paeonol Taminadenant ZILEBESIRAN Ace Inhibitors, Plain Apg777 Marstacimab Pariglasgene Brecaparvovec Baloxavir Marboxil [14C]ZIPALERTINIB Aticaprant More therapies…

    Learn about Your Condition

    Cancer pain Chorea Onychomycosis Ocular myasthenia Oesophageal disorder Osteosarcoma recurrent Mantle cell lymphoma stage IV Liposarcoma Lung neoplasm malignant VEXAS syndrome Pleomorphic liposarcoma Axial spondyloarthritis Biliary adenoma Parkinson's disease Urea cycle disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Still’s disease

  • A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Apremilast
    Greece Italy Spain

  • A Study of MAS825 in Children and Adults with Still’s Disease to Test How Well It Works and How Safe It Is

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Still’s disease
    Investigated Drugs:
    • Human Igg1 Monoclonal Antibody Against Human Il-1 Beta And Human Il-18
    France Germany Italy The Netherlands Spain

  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Diseases:
    • Still’s disease
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Germany Italy Romania Spain

  • Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

    Recruiting

    3 1
    Investigated Diseases:
    • Still’s disease
    Investigated Drugs:
    • Apremilast
    Austria Belgium France Germany Greece Italy +6

  • Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Still’s disease
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Anakinra
    The Netherlands

  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Still’s disease
    Investigated Drugs:
    • Baricitinib
    • Tocilizumab
    Austria Belgium Czechia France Italy Poland +1

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!